HTGF Fonds

Since 2005, the HTGF has launched three funds and has around 900 million euros under management. Almost 600 high-tech start-ups have been financed to date. Investments are made purely based on market criteria. More than 100 companies have already been successfully sold. Grandcentrix became part of the Vodafone family. MSD/Merck took over Rigontec. Amal Therapeutics was bought by Boehringer Ingelheim. N-Fon went public on the German stock exchange and Immunic on the NASDAQ. These are just a few examples of successful exits from our portfolio.

HTGF III

Type: Closed-end fund
Established: 2017
Investment period: 5 years
Fund investors: Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and ALTANA commercial enterprises, BASF, Bayer, Boehringer Ingelheim, B.Braun, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Group, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

HTGF II

Type: Closed-end fund
Established: 2011
Investment period: 6 years
Fund volume: 304 million euros
Fund investors: Federal Ministry of Economics and Technology, KfW and Altana commercial enterprises, BASF, B.Braun , Bosch, Bayer, CEWE, Evonik , Daimler, Deutsche Post, Lanxess, media + more, Metro AG, Qiagen, Innogy SE, SAP, Tengelmann, Telekom, Zeiss

HTGF I

Type: Closed-end fund
Established: 2005
Investment period: 6 years
Fund volume: 272 million euros
Investors: Federal Ministry of Economics and Labour, KfW and commercial enterprises BASF, Siemens, Telekom, Daimler, Bosch, Zeiss